Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today ...

From mind-controlling tech to clinical therapy: An optogenetics roadmap

Researchers at the University of Geneva, together with colleagues in Switzerland, France, the United States and Israel, ...
Science Daily

Gene-edited CAR-T cells erase aggressive T-cell leukemia

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Study identifies misleading genomic sequences of bacteria causing gonorrhea

Northwestern Medicine investigators have identified issues with most genomic sequence data for the Neisseria gonorrhoeae ...
New Scientist

Genetic trick to make mosquitoes malaria resistant passes key test

The rollout of a type of genetic technology called a gene drive for tackling malaria could be edging closer after a lab study ...
Le Lézard

Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting

Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared first-in-human data from the ongoing inMMyCARTM study, a Phase 1 clinical trial ...

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
The Manila Times

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, ...

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...
Taiwan News

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...

Hamilton O. Smith, Who Made a Biotech Breakthrough, Is Dead at 94

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...
Le Lézard

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...